1. Home
  2. PCB vs GLSI Comparison

PCB vs GLSI Comparison

Compare PCB & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PCB Bancorp

PCB

PCB Bancorp

HOLD

Current Price

$24.08

Market Cap

344.5M

Sector

Finance

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$24.00

Market Cap

372.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCB
GLSI
Founded
2003
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
344.5M
372.0M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
PCB
GLSI
Price
$24.08
$24.00
Analyst Decision
Hold
Strong Buy
Analyst Count
2
1
Target Price
$24.50
$50.00
AVG Volume (30 Days)
21.7K
120.2K
Earning Date
04-23-2026
05-19-2026
Dividend Yield
3.67%
N/A
EPS Growth
48.28
N/A
EPS
2.58
N/A
Revenue
$2,899,000.00
N/A
Revenue This Year
$13.73
N/A
Revenue Next Year
$9.07
N/A
P/E Ratio
$9.23
N/A
Revenue Growth
4.51
N/A
52 Week Low
$19.25
$7.78
52 Week High
$24.99
$34.10

Technical Indicators

Market Signals
Indicator
PCB
GLSI
Relative Strength Index (RSI) 62.67 47.27
Support Level $21.12 $24.00
Resistance Level $24.99 $30.08
Average True Range (ATR) 0.59 2.09
MACD -0.03 -0.12
Stochastic Oscillator 55.18 17.02

Price Performance

Historical Comparison
PCB
GLSI

About PCB PCB Bancorp

PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: